Stockscreener 앱 받기
2.16
0.00%
0.00
시간 외 거래:
2.17
0.010
+0.46%
Tempest Therapeutics Inc 주식(TPST)의 최신 뉴스
Aug Fed Impact: Is Tempest Therapeutics Inc gaining market shareCEO Change & Safe Entry Point Identification - baoquankhu1.vn
Exit Recap: Is Tempest Therapeutics Incs growth already priced in2026 Reactions & Real-Time Chart Pattern Alerts - baoquankhu1.vn
Tempest Announces Partnership for TPST-2003 in Preparation for Planned U.S. Registrational Study in 2026 - Bitget
Tempest Therapeutics Inc. (referred to as Tempest) recently disclosed a strategic collaboration regarding its core candidate drug Tpst-2003. - Bitget
Growth Review: Is Tempest Therapeutics Incs growth already priced in2026 Pullback Review & AI Powered Buy/Sell Recommendations - baoquankhu1.vn
Growth Value: Whats the outlook for Tempest Therapeutics Incs sectorWeekly Stock Summary & Verified Short-Term Trading Plans - baoquankhu1.vn
Earnings Recap: Is Tempest Therapeutics Inc stock a value trap2025 EndofYear Setup & Smart Swing Trading Techniques - baoquankhu1.vn
IPO Launch: Is AMBIWS a strong candidate for buy and hold2025 Analyst Calls & Daily Technical Stock Forecast Reports - baoquankhu1.vn
TPST Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Tempest Therapeutics, Inc. (TPST) Stock Forecast & Price Prediction 2026–2030 - CoinCodex
Tempest Therapeutics, Inc.Common Stock (NQ: TPST - FinancialContent
Tempest Therapeutics reports complete response in myeloma trial By Investing.com - Investing.com Australia
EX-99.1 - SEC.gov
Tempest Therapeutics reports complete response in myeloma trial - Investing.com
Tempest Therapeutics Advances TPST-2003 CAR-T with Strong Data - TipRanks
Tempest reports 100% ORR in evaluable TPST-2003 patients, plans U.S. registrational study in 2026 - TradingView
Tempest Therapeutics (TPST) reveals 100% response in TPST-2003 multiple myeloma study - Stock Titan
Tempest Announces Interim Results from Ongoing REDEEM-1 Trial of TPST-2003, Preparing for Potential U.S. Registrational Study in 2026 - Bitget
Tempest Announces Interim Results from Ongoing REDEEM-1 - GlobeNewswire
Tempest myeloma cell therapy hits 100% response in 25 patients, US trial planned - Stock Titan
Why Tempest Therapeutics Inc. stock could outperform in 2025Weekly Profit Recap & Free Community Supported Trade Ideas - mfd.ru
How Tempest Therapeutics Inc. stock reacts to global recession fearsMarket Sentiment Report & AI Enhanced Execution Alerts - mfd.ru
Is Tempest Therapeutics Inc.’s growth already priced inBuy Signal & Daily Oversold Bounce Ideas - mfd.ru
What catalysts could drive Tempest Therapeutics Inc. stock higher2025 Earnings Impact & Free High Return Stock Watch Alerts - mfd.ru
Will Tempest Therapeutics Inc. stock recover after earningsM&A Rumor & Advanced Swing Trade Entry Plans - mfd.ru
TPST Should I Buy - Intellectia AI
How cyclical is Tempest Therapeutics Inc.’s revenue streamEarnings Performance Report & Smart Swing Trading Techniques - mfd.ru
Tempest Therapeutics Highlights Partner-Funded CAR-T Oncology Pipeline - The Globe and Mail
Tempest lays out strategic plan to advance recently acquired dual-targeting CAR-T assets - marketscreener.com
Tempest Therapeutics outlines plans for acquired CAR T assets - bioworld.com
Tempest Therapeutics, Inc. Updates on Oncology Pipeline and Clinical Progress - TradingView
Partner-funded China trials anchor Tempest’s new CAR-T push - Stock Titan
Key facts: Tempest Therapeutics announces management changes; issues warrants - TradingView
Tempest Therapeutics Signs Warrant Agreement With Computershare - TradingView
Tempest Therapeutics (NASDAQ: TPST) closes CAR T acquisition and names new CEO - Stock Titan
12 Health Care Stocks Moving In Thursday's Pre-Market Session - Benzinga
Tempest Therapeutics completes acquisition of CAR-T assets By Investing.com - Investing.com India
Tempest Therapeutics completes acquisition of CAR-T assets - Investing.com
Tempest Therapeutics Closes All-Stock Transaction to Acquire Next-Generation CAR-T Assets and Appoints Matt Angel as CEO - Quiver Quantitative
Tempest Announces Closing of Strategic Acquisition of Dual-Targeting CAR-T Assets - GlobeNewswire
Cancer biotech Tempest retools around dual CAR-Ts and new CEO - Stock Titan
Tempest Therapeutics (TPST) Price Target Increased by 22.22% to 11.22 - Nasdaq
Tempest Therapeutics Announces New Leadership and Acquisition - MSN
Will Tennessee Valley Authority benefit from AI trendsMarket Sentiment Summary & Weekly High Momentum Picks - baoquankhu1.vn
Tempest Therapeutics Stockholders Extend Rights Plan and Approvals - The Globe and Mail
What’s the outlook for Tempest Therapeutics Inc.’s sectorPortfolio Gains Report & Consistent Return Investment Signals - mfd.ru
Tempest Therapeutics (NASDAQ: TPST) wins approval for rights plan, share issuance and equity pool - Stock Titan
Investment Report: Is Tempest Therapeutics Inc stock a value trapJuly 2025 Final Week & Daily Stock Trend Watchlist - baoquankhu1.vn
Aug Decliners: Is Tempest Therapeutics Inc stock a top performer YTD2025 EndofYear Setup & Risk Controlled Stock Pick Alerts - baoquankhu1.vn
Tempest Therapeutics stock surges after H.C. Wainwright upgrade By Investing.com - Investing.com Australia
Tempest Therapeutics stock surges after H.C. Wainwright upgrade - Investing.com
H.C. Wainwright upgrades Tempest Therapeutics stock rating to Buy with $11 target - Investing.com India
HC Wainwright & Co. Upgrades Tempest Therapeutics (TPST) - Nasdaq
1.20%
0.06%
자본화:
|
볼륨(24시간):